Olivia Lambert was a bright and happy little girl with an infectious smile and a fun-loving spirit. Diagnosed with stage 4 neuroblastoma at age two and a half, she fought the disease bravely for six years. Her legacy and spirit continue with the appointment of Dr Joshua McCarroll as the Olivia Lambert Team Leader.
This week we’re looking at Drug Discovery – the development of new cancer treatments. Because it’s only with more effective, less toxic cancer drugs that we’ll be able to save the life of every child with cancer and improve their long-term health.
Our scientists have been forging alliances in China that will open the door to research collaborations and speed the progress of childhood cancer research.
Last week a group of our scientists were in San Francisco attending The Advances in Neuroblastoma Research (ANR) conference. One of them, Dr Jayne Murray, tells us about it.
In the approach to Mother’s Day, one of our incredible supporters, Sasha, contacted us about some words she had written as she was thinking about the approach of her first Mother’s Day without her son Byron. Byron sadly passed away from Neuroblastoma on the 12th August 2017, just 9 days before his 3rd birthday.
Our scientists have found a way to rein in a cancer-causing gene called MYCN and slow down the growth of the childhood cancer neuroblastoma.
Money raised by the Sydney Airport Community Christmas Giving Appeal will support an innovative project to find better treatments for neuroblastoma.
Dr Marion Le Grand is a Research Officer in our Tumour Biology and Targeting Program. She tells us what she does, and why she came all the way from France to do it.
Without treatment, Lexie had two weeks to live. Overnight she became ‘the kid with cancer’.
How we got to now in our understanding of MRP1, a protein that ejects chemotherapy drugs from tumour cells and stops them stopping cancer. We're exploring future drugs that target it.